Krystal Biotech subsidiary announces results from Phase 1 study of KB304

Jeune Aesthetics, a wholly owned subsidiary of Krystal Biotech (KRYS), announced positive safety and efficacy results, including significant improvements in key skin aesthetic attributes such as wrinkles and elasticity, in PEARL-2, a randomized, double-blind, placebo-controlled Phase 1 study evaluating KB304, for the treatment of wrinkles of the decollete. Meaningful aesthetic improvements were reported following KB304 treatment with clear and statistically significant advantages over placebo as evaluated by both the investigator and subjects using the Global Aesthetic Improvement Scale, GAIS. As assessed by SSQ, 81.8% of subjects receiving KB304 reported improved satisfaction with their wrinkles’ appearance three months after treatment, compared to 14.3% of subjects receiving placebo. The KB304 safety profile was consistent with prior clinical experience in KB301. Adverse events were mild-to-moderate and mostly reported after the first dose but substantially tapered off with subsequent doses. No severe or drug-related serious adverse events were reported.